![Graham Cooper](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Graham Cooper
Vorsitzender bei KEZAR LIFE SCIENCES, INC.
Vermögen: - $ am 31.05.2025
Profil
Graham K.
Cooper currently works at Kezar Life Sciences, Inc., as Chairman from 2022 and Beam Therapeutics, Inc., as Independent Director from 2019.
Mr. Cooper also formerly worked at Applied Molecular Transport, Inc., as Executive Chairman from 2022 to 2023, Deutsche Bank Securities, Inc., as Director-Health Care Investment Banking from 1997 to 2006, Celladon Corp., as Independent Director from 2013 to 2016, Bioniz Therapeutics, Inc., as Director, Unity Biotechnology, Inc., as Independent Director from 2017 to 2022, Geron Corp., as Chief Financial Officer & EVP-Business Development in 2012, Orexigen Therapeutics, Inc., as Chief Financial Officer, Treasurer & Senior VP in 2011, Receptos LLC, as CFO, CAO, Head-Investor & Media Relations from 2014 to 2015, Deloitte & Touche LLP, as Accountant from 1992 to 1995, and Assembly Biosciences, Inc., as Chief Operating, Financial & Accounting Officer from 2018 to 2019.
Mr. Cooper received his undergraduate degree from the University of California, Berkeley and Masters Business Admin degree from Stanford Graduate School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.06.2025 | 0 ( -.--% ) | - $ | 31.05.2025 | |
| 20.06.2024 | 0 ( -.--% ) | - $ | 31.05.2025 |
Aktuelle Nachrichten zu Graham Cooper
Aktive Positionen von Graham Cooper
| Unternehmen | Position | Beginn |
|---|---|---|
| KEZAR LIFE SCIENCES, INC. | Vorsitzender | 12.05.2022 |
| BEAM THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 10.10.2019 |
Ehemalige bekannte Positionen von Graham Cooper
| Unternehmen | Position | Ende |
|---|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Vorsitzender | 08.03.2023 |
| UNITY BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 25.05.2022 |
| ASSEMBLY BIOSCIENCES, INC. | Finanzdirektor/CFO | 01.04.2019 |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.03.2016 |
| RECEPTOS INC | Finanzdirektor/CFO | 27.08.2015 |
Ausbildung von Graham Cooper
University of California, Berkeley | Undergraduate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| GERON CORPORATION | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| KEZAR LIFE SCIENCES, INC. | Health Technology |
| BEAM THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Deutsche Bank Securities, Inc.
 Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve. | Finance |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Bioniz Therapeutics, Inc.
 Bioniz Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA. | Commercial Services |
Applied Molecular Transport, Inc.
 Applied Molecular Transport, Inc. BiotechnologyHealth Technology Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood on November 21, 2016 and is headquartered in Menlo Park, CA. | Health Technology |
